Circulating tumour DNA (ctDNA) analysis offers additive prognostic insight beyond PSA and imaging: in a post-hoc analysis of the TheraP trial, patients with low ctDNA% had a 100% biochemical response rate and a markedly longer median PFS (14.7 vs. 6.0 months) with [177Lu]Lu-PSMA-617, independent of PSMA-PET imaging parameters. Here, FOLH1 is linked to neoplasm.